Savings for Americans and American Innovation: U.S. and UK Agree on Drug Pricing Deal
04 December 2025
Phil Kerpen, President and Founder of American Commitment, discusses the recent drug-pricing deal negotiated by the Trump administration with the United Kingdom, the multiple benefits the agreement will have for Americans and drug innovation, why taxpayer subsidies to health insurers will not lower healthcare costs, and why price controls for credit card transactions are a bad idea.
0:00 0:00

Related Podcasts

Celebrating 250 Years of American Exceptionalism
13 June 2026
Rowena Itchon, Chief Operating Officer at the Pacific Research Institute, discusses a series of short videos released by PRI to bring to life the unsung heroes who have contributed remarkably to American innovation and success over the last 250 years and who embodied the spirit and values that make this country truly exceptional: self-reliance, innovation and civic responsibility.
Regulatory Round Up and the Latest on the U.S. Steel/Nippon Steel Deal
09 January 2025
Ryan Young, Senior Economist and Trade Policy Expert at the Competitive Enterprise Institute, discusses last year’s regulatory highlights (and low points), the regulatory outlook for 2025, including the potential impact of DOGE on the volume of federal regulations, and President Biden’s baseless decision to block Nippon Steel’s purchase of U.S. Steel.
The Downsides of Most Favored Nation Drug Pricing
17 September 2020
Sally Pipes, President, CEO and Thomas W. Smith Fellow in Health Care Policy at the Pacific Research Institute, discusses President Trump’s recent executive order regarding drug pricing, how importing foreign drug price controls could curtail innovation and limit access to the newest drugs, and why the timing of such a policy is wrong amid the ongoing COVID-19 pandemic.
Drug Pricing Executive Orders Are a Prescription for Disaster
14 August 2020
Timothy Lee, Senior Vice President of Legal and Public Affairs at the Center for Individual Freedom, discusses President Trump's executive orders on drug pricing and the negative consequences of government price controls on innovation and to consumers.
Prescription Drug Pricing: Helpful Fixes vs. Foreign Price Controls
03 May 2019
Phil Kerpen, President of American Commitment, discusses prescription drug prices, the fundamental problems with importing foreign price controls, and the steps Congress can take to improve the system.
American People Continue to Reject Obama's Global Climate Deal
09 January 2015
Leighton Steward, Chairman of Plants Need CO2, discusses a report from a team of former NASA scientists that concludes there is no convincing physical evidence of catastrophic human-caused global warming and the American people's rejection of President Obama's Global Climate Deal.